Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Day One Biopharmaceuticals (DAWN) Operating Expenses (2022 - 2025)

Day One Biopharmaceuticals (DAWN) has disclosed Operating Expenses for 4 consecutive years, with $81.2 million as the latest value for Q4 2025.

  • For Q4 2025, Operating Expenses fell 14.14% year-over-year to $81.2 million; the TTM value through Dec 2025 reached $285.9 million, down 17.94%, while the annual FY2025 figure was $285.9 million, 17.94% down from the prior year.
  • Operating Expenses was $81.2 million for Q4 2025 at Day One Biopharmaceuticals, up from $64.0 million in the prior quarter.
  • The five-year high for Operating Expenses was $123.0 million in Q2 2024, with the low at $27.7 million in Q1 2022.
  • Historically, Operating Expenses has averaged $61.7 million across 4 years, with a median of $61.8 million in 2023.
  • The largest annual shift saw Operating Expenses skyrocketed 149.72% in 2024 before it crashed 44.0% in 2025.
  • Over 4 years, Operating Expenses stood at $42.7 million in 2022, then soared by 39.24% to $59.5 million in 2023, then skyrocketed by 58.85% to $94.5 million in 2024, then decreased by 14.14% to $81.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Operating Expenses were $81.2 million in Q4 2025, $64.0 million in Q3 2025, and $68.9 million in Q2 2025.